Q1 smashed expectations; outlook revised higher
14/05/25 -"Q1 results came in much ahead of expectations, driven by robust momentum for Lundbeck’s four key products. Consequently, the management upgraded its full-year guidance. Overall, after a massive ..."
Pages
60
Language
English
Published on
14/05/25
You may also be interested by these reports :
15/05/25
Merck’s decision to provide detailed FY guidance was overshadowed by the significant impact of US President Trump’s actions. Consequently, ...
15/05/25
Sanofi’s share price is down c.15% since its March 2025 highs, largely owing to the US tariff and drug pricing uncertainty within the sector, ...
14/05/25
Q1 results came in much ahead of expectations, driven by robust momentum for Lundbeck’s four key products. Consequently, the management upgraded its ...
14/05/25
As reverters to the mean, Pharmas have been a waste of time since Covid (say 5 years), over 2 years, 1 year and ytd. This is computed on an ...